Pre-Approval Access With Amivantamab in Patients With Metastatic Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations Who Have Failed Platinum-Based Chemotherapy
Latest Information Update: 02 Nov 2021
At a glance
- Drugs Amivantamab (Primary)
- Indications Non-small cell lung cancer
- Focus Expanded access; Therapeutic Use
- Sponsors Janssen Research & Development
- 14 Jun 2021 Status changed from recruiting to completed.
- 03 Dec 2020 According to a Janssen Pharmaceuticals media release, company established this expanded access program for patients in the U.S. who may be eligible to obtain access to amivantamab during review of the BLA.
- 27 Oct 2020 New trial record